" BetterLife Pharma (CSE:BETR) closes private placement

BetterLife Pharma (BETR) has closed a non-brokered private placement for gross proceeds of $474,000.

" Red Light Holland (CSE:TRIP) utilizing 3D movement data for psychedelic therapy

Red Light Holland (TRIP) subsidiary Radix Motion has received an International Preliminary Report on Patentability on the patent application filed in 2020. ...

" Algernon (CSE:AGN) receives FDA Orphan Drug Designation for Ifenprodil to treat Idiopathic Pulmonary Fibrosis

Algernon Pharmaceuticals (AGN) has been granted Orphan Drug Designation (ODD) for Ifenprodil to treat Idiopathic Pulmonary Fibrosis (IPF).

" Irwin Naturals (CSE:IWIN) leverages household brand status

Irwin Naturals (IWIN) reached a binding, arms-length agreement to acquire Serenity Health this past November.

" Nova (CSE:NOVA) submits Phase II A psilocybin clinical trial application to Health Canada

Nova Mentis Life Science Corp. (NOVA) has submitted the Phase II A psilocybin clinical trial application to Health Canada.

" Lobe Sciences (CSE:LOBE) advances clinical development plans for its proprietary psilocin product

Lobe Sciences (LOBE) released an update for its clinical development plans for its proprietary Psilocin-based compound L-130.

" Psyence Group (CSE:PSYG) signs distribution agreement with This Works Products Ltd.

Psyence Group (PSYG) and The Goodleaf Company have signed an exclusive distribution agreement with This Works Products Ltd.

" The Good Shroom Co. (TSXV:MUSH) reports financial results with over 6X growth in revenue

Good Shroom (MUSH) announced its financial & operational highlights for the fiscal year ended July 31, 2022.

" Field Trip Health & Wellness (TSXV:FTHW) announces executive appointments and schedules Q2 conference call

Field Trip Health & Wellness (TSXV:FTHW) has added two senior executives to its leadership team.

" Clearmind Medicine (CSE:CMND) closes US$7.5 million public offering

Clearmind Medicine (CMND) has closed its underwritten public offering of 1,153,847 common shares.

" Nova Mentis (CSE:NOVA) signs research contract with KGK Science for Phase II A clinical trial

Nova Mentis (NOVA) has signed a research services agreement with KGK Sciences for a Phase II A clinical trial to test psilocybin on patients
Algernon Pharmaceuticals Inc.

" Algernon Pharmaceuticals (CSE:AGN) screens first subject in Phase 1 DMT Human Stroke Study

Algernon (AGN) is screening subjects for its Phase 1 clinical study of AP-188, N-Dimethyltryptamine (DMT, a hallucinogenic drug) in the Netherlands.

" Mindset Pharma (CSE:MSET) signs sales agreement with PharmAla (CSE:MDMA)

Mindset Pharma (MSET) has signed a sales agreement with PharmAla Biotech (MDMA).

" Nirvana (CSE:NIRV) appoints Sheldon Inwentash to the Board of Directors

Nirvana Life Sciences (NIRV) has appointed Sheldon Inwentash to the company’s Board of Directors.

" Psyched Wellness (CSE:PSYC) signs purchase agreement with Choice Wholesale for 60,000 units of ‘Calm’

Psyched Wellness (PSYC) has signed a purchase agreement with Choice Companies Wholesale and Distribution.
Biomind Labs Inc. - CEO, Alejandro Antalich.

" Biomind Labs (NEO:BMND) sees positive results from its phase 2 depression treatment trial

Biomind Labs (BMND) announced positive initial results from the first part of its Phase II trial for treatment-resistant depression.
Numinus Wellness Inc. CSO, Dr. Paul Thielking.

" Numinus (TSX:NUMI) Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness

Numinus Wellness (NUMI) has launched its ketamine for chronic and serious medical illness program in Utah, British Columbia, and Quebec.

" HYTN (CSE:HYTN) awarded controlled drugs & substances dealer’s license

HYTN Innovations’ (HYTN) subsidiary, HYTN Cannabis, has been awarded a controlled drugs and substances dealer’s license for psilocybin by Health Canada.